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Abstract
Immunoglobulin-like transcript (ILT) 3 and 4 are inhibitory receptors that modulate
immune responses. Their expression has been reported to be affected by
interferon, offering a possible mechanism by which this cytokine exerts its
therapeutic effect in multiple sclerosis, a condition thought to involve excessive
immune activity. To investigate this possibility, we measured expression of ILT3 and
ILT4 on immune cells from multiple sclerosis patients, and in post-mortem brain
tissue. We also studied the ability of interferon beta, alone or in combination with
vitamin D, to induce upregulation of these receptors in vitro, and compared
expression levels between interferon-treated and untreated multiple sclerosis
patients. In vitro interferon beta treatment led to a robust upregulation of ILT3 and
ILT4 on monocytes, and dihydroxyvitamin D3 increased expression of ILT3 but not
ILT4. ILT3 was abundant in demyelinating lesions in postmortem brain, and
expression on monocytes in the cerebrospinal fluid was higher than in peripheral
blood, suggesting that the central nervous system milieu induces ILT3, or that ILT3
positive monocytes preferentially enter the brain. Our data are consistent with
involvement of ILT3 and ILT4 in the modulation of immune responsiveness in
multiple sclerosis by both interferon and vitamin D.
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Introduction
Immunoglobulin-like transcripts (ILT), also known as leukocyte immunoglobu-
lin-like receptors (LILR) belong to a large family of activating and inhibitory
receptors that modulate the threshold and amplitude of immune cell activation
[1, 2]. Immune inhibitory ILT family members such as ILT3 (CD85k, LILRB4)
and ILT4 (CD85d, LILRB2) are characterized by an extracellular immunoglobu-
lin-like domain responsible for ligand-binding, and a long cytoplasmatic tail
containing immunoreceptor-tyrosine based inhibitory motifs (ITIM) which
recruit inhibitory phosphatases and transduce a negative signal into the cell [3]. A
high expression of ILT3 and ILT4 on the cell surface of antigen-presenting cells
renders them tolerogenic, inhibiting T cell proliferation and favouring the
generation of CD8+ T suppressor cells [4, 5, 6, 7].
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the
central nervous system (CNS). It has been hypothesized that an aberrant
activation of autoreactive T cells in the peripheral immune compartment due to
failure of peripheral tolerance mechanisms triggers T-cell mediated CNS
inflammation in MS [8]. Accordingly, impaired expression of molecules involved
in the regulation of T cell activation such as PD-1 and other B7 family members
has been found to exacerbate CNS inflammation in animal models of the disease
[9, 10, 11]. While the role of ILT3 and ILT4 as regulators of T cell activation and
mediators of tolerance is well recognized in transplant and cancer immunology
[12, 13, 14], little is known about the influence of these receptors on autoimmune
diseases.
Here we show that the beneficial effects of IFN beta in multiple sclerosis may in
part be mediated by modulation of ILT3 and ILT4 expression on APC.The role of
immunoregulatory receptors in CNS inflammation is further highlighted by their
enrichment in cerebrospinal fluid and an upregulation of ILT3, ILT4, and B7-H3
in acute MS lesions.
Results
ILT3 and ILT4 expression on monocytes is upregulated by in vitro
IFN beta treatment
CD14+ monocytes derived from treatment-nai¨ve patients with RRMS (n524) or
CIS (n56) and healthy controls (n514) were analyzed for surface expression of
ILT3 and ILT4 by flow cytometry. Baseline expression of ILT3 and ILT4 as
assessed by comparing the specific fluorescent indices (SFI) did not differ
significantly between these groups (Fig. 1A). Regarding the percentage of ILT3
positive cells, CIS patients tended to have higher numbers of ILT3+CD14+ cells
(mean +/-S.E.M.: 55.03+/25.85; p,0.05) compared to RRMS patients (34.78 +/
25.73) and healthy controls (25.54 +/24.16). No significant differences
concerning the percentages of ILT4+CD14+ cells were observed between these
groups (data not shown).
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Fig. 1. IFN beta induces ILT3 and ILT4 expression in monocytes. (A) The baseline expression of the
immune inhibitory receptors ILT3 and ILT4 on peripheral blood derived CD14+ monocytes assessed by
comparing the specific fluorescent index (SFI 5 geo mean ILT/geo mean IgG1) does not differ significantly
between RRMS (n524) or CIS patients (n56) and healthy donors (HD, n514) as demonstrated by flow
cytometry. (B) In vitro IFN beta (1000IE/ml, 16 h) treatment induces ILT3 and to a lesser extent ILT4 protein
expression in CD14+ monocytes from RRMS patients (n524). In addition the monocytic expression of the
coinhibitory B7 family member B7-H1 is upregulated, whereas B7-H3 is not significantly affected. The specific
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Furthermore, we could not detect any differences regarding the baseline
expression of B7-H1 and B7-H3 (data not shown). In vitro IFN beta treatment of
PBMC resulted in a strong upregulation of both ILT3 and ILT4 on CD14+
monocytes (Fig. 1 B, D). The percentage of ILT3+ monocytes was almost doubled
from 35% to 68% and the percentage of ILT4 monocytes increased from 47% to
66% (Fig. 1C). The extent of ILT3 and ILT4 induction was comparable to that of
B7-H1, a known target protein of IFN beta [15], whereas the expression of the
novel B7-homologue B7-H3 remained unaffected (Fig. 1 B). Upregulation of ILT3
by IFN beta was induced in isolated monocytes indicating that lymphocytes do
not contribute to this effect (Fig. 1 E). Upregulation of CD86 expression was
monitored as a positive control in each experiment (data not shown).
Additive effects of IFN beta and Vitamin D3 on monocytic ILT3
expression
1a,25 Dihydroxyvitamin D3 (1a,25(OH)2D3) has been reported to induce ILT3
but not ILT4 expression on antigen-presenting cells [16]. Using flow cytometry we
assessed the impact of 1a,25(OH)2D3 (100 nM) alone or in combination with
IFN beta (1000 IE) on the expression of these immunoregulatory molecules on the
surface of CD14+ monocytes derived from a second cohort of RRMS patients
(n59, Fig. 2) and healthy controls (n58, S1 Fig.). In line with previous findings
1a,25(OH)2D3 was found to be a potent inducer of ILT3 but not ILT4 expression.
Combined stimulation with IFN beta had a strong additive effect, leading to high
levels of membrane bound ILT3 protein on CD14+ cells (Fig. 2). In contrast ILT4
levels, which were downregulated in 1a,25(OH)2D3 only treated cells, were
restored back to normal levels in the presence of both reagents (Fig. 2). Similar
trends were observed in healthy controls; however, the downregulation of ILT4 by
1a,25(OH)2D3 and the restoration of ILT4 surface levels by a combined treatment
did not reach the level of significance in controls (S1 Fig.).
ILT3 mRNA is upregulated in PBMC from IFN beta treated RRMS
patients
To corroborate our in vitro findings, we analyzed the expression of ILT3 mRNA in
PBMC derived from treatment nai¨ve RRMS patients and patients undergoing
long-term treatment with either IFN beta-1b (Betaferon) or IFN beta-1a (Rebif)
by quantitative PCR. In line with our in vitro findings, expression of ILT3 mRNA
fluorescent index is shown (grey bar: control; black bar: IFN beta). (C) The percentage of CD14+ monocytes
expressing the immune inhibitory ILT is strongly increased following incubation with IFN beta as assessed by
flow cytometry (n524; grey bar: control; black bar: IFN beta 1000 IE/ml, 16 h). (D) A representative flow
cytometry experiment is shown. Please note, for simplification the isotypic control for ILT4 (IgG2a) is not
shown in this picture. (E) IFN beta induces ILT3 mRNA in purified CD14+ monocytes derived from healthy
donors (n56). Relative expression of ILT3 mRNA was assessed by quantitative PCR (Mann-Whitney U test; *
p,0,05, ** p,0,005; bars are presented as mean ¡ S.E.M)
doi:10.1371/journal.pone.0115488.g001
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was 2.5 fold higher in IFN beta treated compared to untreated RRMS patients
(Fig. 3). Of note, there were no differences between the two preparations of IFN
beta concerning the expression of ILT3 mRNA.
Fig. 2. Effects of 1a,25 Dihydroxyvitamin D3 in combination with IFN beta on monocytic ILT3 and ILT4 expression. PBMC derived from RRMS
patients (n59) were stimulated with 1a,25 Dihydroxyvitamin D3 (100 nM) and/or IFN beta (1000 IE) over a 48 h period. ILT3 and ILT4 protein expression on
CD14+ cells was assessed by flow cytometry. The fold induction is shown (mean + SEM). A repeated measurement ANOVA with Bonferroni multiple
comparison test was performed to assess statistical significance (* p,0,05; **p,0.005).
doi:10.1371/journal.pone.0115488.g002
Fig. 3. ILT3 mRNA is upregulated in PBMC derived from IFN beta treated RRMS patients. Relative
expression of ILT3 mRNA in PBMC derived from IFN beta treated patients with RRMS (n510) and sex- and
age matched controls (n510) as assessed by quantitative PCR (Mann-Whitney U test, **p,0,005). Bars are
presented as mean ¡ S.E.M.
doi:10.1371/journal.pone.0115488.g003
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Soluble ILT3 serum concentrations do not seem to be affected by
IFN beta treatment
In addition to membrane-bound ILT3, soluble ILT3 (sILT3) has been described
and presumed to result from proteolytic cleavage from the cell surface or from
alternatively spliced ILT3 isoforms that lack the transmembrane domain.
Previously, sILT3 was detected in sera from patients with various malignancies,
giving rise to the hypothesis that sILT3 may play a role in the immune evasion of
tumor cells [12]. We asked whether patients with multiple sclerosis (n515) would
show detectable serum levels of sILT3 and whether these levels would be
modulated by IFN beta treatment. Serum from melanoma patients about to start
(n53) or already undergoing IFN alpha therapy (n58) served as a control. We
failed to detect sILT3 in all but 2 patients with RRMS which is in the range of
healthy controls [12]. From one of the RRMS patients displaying detectable levels
of sILT3 protein two samples from before and 3 months after initiation of IFN
beta therapy were available. Interestingly these showed a remarkable consistency
over time without any impact of IFN beta therapy (before: 26 ng/ml, after: 28 ng/
ml; S1 Table). Also from 8 patients with malignant melanoma, only 2 had
detectable levels of sILT3. An effect of IFN alpha treatment was not detected in the
3 melanoma patients in which pre- and post-treatment samples were available (S1
Table).
ILT3 expressing monocytes in CSF
Flow cytometry of paired blood and CSF specimens demonstrated a higher level of
ILT3 surface protein on CSF-derived than on blood-derived CD14+ monocytes,
both in patients with and without neuroinflammatory diseases (Fig. 4A, B).
Accordingly the percentage of ILT3+ CD14+ monocytes in the CSF ranged from
45% up to 95% demonstrating an enrichment of ILT3+ monocytes in the CSF.
There were no statistically significant differences between patients with non-
inflammatory neurological diseases (n514) and those with inflammatory
neurological diseases (n58) concerning the percentage of ILT3+monocytes or the
level of ILT3 expression. This holds true for both, CSF and blood samples in this
cohort (Fig. 4A).
Expression of the immunoregulatory molecules ILT3, ILT4, and
B7-H3 in MS lesions and control tissue
Lesions were characterized and graded for the activity of demyelination by luxol
fast blue, hematoxylin/eosin staining and CD68 immunohistochemistry (Fig. 5).
Lesions were characterized as active when they showed recent demyelination,
macrophage infiltration, and perivascular cuffing. Seven lesions were classified as
active lesions. One lesion was defined as chronic inactive. As controls, three
samples from white matter of control brains and one sample from normal
appearing white matter of a MS brain were included. Quantitative RT-PCR
revealed an upregulation of ILT3, ILT4, and B7-H3 transcripts in active lesions
IFN Beta and Vitamin D Modulate Expression of ILT3 in MS
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and in the one chronic inactive lesion compared to control brain and normal
appearing white matter of a MS brain (Fig. 6). B7-H1 has been previously
reported to be upregulated on microglial/macrophage-like cells within active MS
lesions. Due to the limited amount of human material, we here refrained from
reproducing the results on B7-H1 obtained by Ortler et al. [17].
Discussion
The immune system has to preserve immune tolerance to self while maintaining
the ability to fight foreign pathogens. In addition to central tolerance mechanisms,
Fig. 4. CSF monocytes express high levels of ILT3. (A) Paired blood and CSF samples were analyzed for expression of ILT3 on CD14+ monocytes by
flow cytometry. The specific fluorescent index is shown. Patients were categorized according to their diagnosis as having non-inflammatory neurological
diseases (NIND, n514; marked by dot) or inflammatory neurological disease (IND, n58) including 5 MS patients (marked by x) and 3 patients with other
inflammatory neurological disease (diamond). A Mann-Whitney U test was performed to assess statistical significance. (B) Histogram of a representative
staining in a patient with NIND.
doi:10.1371/journal.pone.0115488.g004
Fig. 5. Characterization of MS tissue blocks. (A) Overview of a demyelinating lesion with perivascular
cuffing. Myelin is stained blue with LFB. Lesion border is indicated by a dotted line. Perivascular cuff is marked
by an arrow. Scale bar indicates 400 mm. (B) CD68 positive macrophages in demyelinated lesion. CD68
positive cells are stained brown and marked by arrows. Scale bar indicates 50 mm. (C) Demyelinated lesion in
higher magnification with cells reminiscent of macrophages that phagocytosed LFB positive myelin debris
(marked with arrows). Scale bar indicates 50 mm.
doi:10.1371/journal.pone.0115488.g005
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the control of T cell activation in the periphery is essential to prevent
autoimmunity [18]. Both antigen-presenting cells and T cells are endowed with a
large repertoire of activating and inhibitory molecules. It is the integration of
these signals that keeps T cells in check and dictates the outcome of an APC-T cell
encounter [11, 19]. Here we report that IFN beta, an immunomodulatory drug
widely used to treat multiple sclerosis, induces the expression of the immune
inhibitory receptors ILT3 and ILT4 on monocytes. Our findings confirm in vitro
data by Jensen et al. [20] and further show that upregulation of monocytic ILT3
expression by IFN beta is not an in vitro artefact, but can also be found in patients
with relapsing-remitting multiple sclerosis undergoing IFN beta therapy as
demonstrated by quantitative PCR. In addition, we demonstrate that the extent of
ILT3 and ILT4 upregulation in monocytes is comparable to that of the
coinhibitory molecule B7-H1 which has been reported as a target of IFN beta
therapy in MS [21]. In contrast, the expression level of the coinhibitory B7
homologue B7-H3 remained unaffected, pointing to a selective effect of IFN beta
on these immunomodulatory molecules and monocyte immunobiology.
Vitamin D insufficiency has emerged as a potential risk factor for multiple
sclerosis and may be associated with a higher disease activity [22, 23, 24, 25].
Larger studies addressing effects of oral high-dose vitamin D are on their way
[26], including a phase II trial of vitamin D and IFN beta cotreatment (SOLAR,
NCT01285401). A previous clinical study suggested that vitamin D and IFN beta
Fig. 6. ILT3, ILT4 and B7-H3 mRNA expression in MS tissue samples. Expression of ILT3, ILT4, and B7-
H3 in CNS autopsy samples measured by quantitative PCR and normalized to PUM1. For each gene, results
from normal white matter from control brains are shown on the left (open circles), and results from 7 active
lesions (black squares) and 1 inactive lesion (grey square) and 1 normal appearing white matter (open
square) are shown on the right. Vertical axis shows the expression relative to PUM1 calculated according to
the formula in the Methods section (*p,0.05, Mann-Whitney U test).
doi:10.1371/journal.pone.0115488.g006
IFN Beta and Vitamin D Modulate Expression of ILT3 in MS
PLOS ONE | DOI:10.1371/journal.pone.0115488 December 31, 2014 8 / 15
act together in modulating disease activity in MS [27]. However, on a cellular level
the mechanisms of this interaction remain elusive. The bioactive form of vitamin
D, 1a,25(OH)2D3 has previously been reported to be a potent inducer of ILT3 on
APC [16]. Here we demonstrate that IFN beta and 1a,25(OH)2D3 work together
in inducing ILT3 receptor expression in monocytes. Thereby, vitamin D co-
treatment could contribute to the beneficial effects of the disease-modifying drug.
Interestingly, IFN beta and 1a,25(OH)2D3 have contrasting effects on ILT4
expression levels on monocytes. By counteracting the effects of 1a,25(OH)2D3 on
ILT4 expression IFN beta may further contribute to the tolerogenic properties of
these cells.
Interestingly, ILT3 has bidirectional signalling properties [28]. In addition to
the signal transduced via its intracellular domain, the extracellular Ig-like domain
of ILT3 binds to T cells and may directly modulate. [28]. Accordingly, soluble
forms of ILT3 are effective inhibitors of T cell proliferation, even in the absence of
APC and may be of interest for future therapeutic use as immunomodulators in
autoimmune diseases. [6, 12, 28, 29].
So far, ILT3 serum levels have not yet been systematically analyzed in patients
with autoimmune diseases. In our study only 2 out of 15 MS patients tested
positive for soluble ILT3 in serum, which is in the range of healthy individuals
[12]. As a positive control we studied patients with melanoma. In contrast to a
previous publication [12], the rate of detectable sILT3 in serum was low in this
cohort (,25%). The discrepancy of our findings may be due to the fact that the
previous publication was confined to patients with advanced-stage melanoma,
while our cohort also included patients that, although at high risk for spreading,
still had localized disease. In addition the patients examined by Suciu-Foca et al
were enrolled for treatment with high-dose IL-2 which may also account for
higher sILT3 serum levels in their cohort [12].
Current concepts of MS pathogenesis presume that breakdown of immune
tolerance in the periphery is an initiating step in the cascade that finally leads to
CNS infiltration by autoreactive T cells, demyelination and axonal loss [11]. Given
the potent inhibitory capacity of ILT3 on T cell activation and proliferation,
upregulation of this immune inhibitory receptor on monocytes in IFN beta-
treated MS patients may indeed represent a therapeutic mechanism that helps to
prevent overshooting immune responses. Demonstration of increased ILT3
expression on CSF monocytes and within active MS lesions suggests that the
immunomodulatory effects of ILT3 are not restricted to the peripheral immune
compartment but may also play a role at the site of inflammation in MS.
Compared to the peripheral blood, CSF monocytes display high levels of ILT3 on
their surface, with ILT3+ monocytes accounting for approximately two thirds of
CD14+ cells in the CSF. This enrichment of ILT3+ monocytes in CSF can be
observed not only in patients with inflammatory but also in individuals with non-
inflammatory neurological diseases. Accordingly, the high expression of ILT3 on
CSF monocytes seems not to be reactive to neuroinflammation but rather a
primary attribute of monocytes in the CSF, suggesting a possible involvement of
IFN Beta and Vitamin D Modulate Expression of ILT3 in MS
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ILT3 in the basic mechanisms of CNS immune surveillance. However, since CSF
was not available from healthy donors this remains speculative.
Silencing of ILT3 in monocyte-derived dendritic cells potentiates stimulus-
induced release of chemokines, that may be involved in T cell trafficking to the
CNS [5]. Therefore, ILT3 expressing monocytes within CSF-filled spaces have the
potential not only to dampen T cell activity but also to counteract the attraction of
pathogenic cells. Further evidence for a possible role of ILT3 at the site of
inflammation in MS comes from our expression analysis demonstrating the
presence of ILT3 in active MS lesions but not in normal-appearing white matter
and white matter from control brains. Since immunohistochemical staining of
ILT3 in brain tissue could not be established with the available antibodies we
cannot tell the exact cellular source of ILT3 expression. However, since ILT3
expression is confined to professional and non-professional APC [2, 29] it can be
assumed that macrophages and microglia account for a large fraction of the ILT3-
expressing cells. Similar to ILT3, ILT4 was also found to be upregulated in active
MS lesions.However, in contrast to ILT3, ILT4 was not analyzed on CSF
monocytes in this study which limits the conclusions drawn from this finding.
This work provides in vitro and ex vivo evidence for an induction of the
immune inhibitory molecules ILT3 and ILT4 on APCs by IFN beta. The IFN
mediated induction of ILT3 can also be potentiated by vitamin D. Increased
expression of ILT3 on CSF monocytes and in MS lesions together with other
inhibitory receptors indicate a pivotal role of these molecules in the regulation of
neuroinflammation. Targeting ILT3 may therefore represent a future therapeutic
option in autoimmune diseases.
Materials and Methods
Clinical Samples
The study was approved by the local ethics committee (Nr. 4203, University
Erlangen-Nuremburg). Written informed consent was obtained from all patients
and and all clinical investigations have been conducted according to the principles
expressed in the Declaration of Helsinki. Patients with relapsing-remitting
multiple sclerosis (RRMS) according to the revised McDonald criteria (2005) [30]
and clinically isolated syndrome (CIS) were eligible for participation in this study.
All patients were nai¨ve to immunomodulatory (IFN beta, glatiramer acetate,
dimethylfumarate, teriflunomide, fingolimod, natalizumab, alemtuzumab) and
immunosuppressive drugs (mitoxantrone, cyclophosphamide) except for patients
presented in Fig. 3 from whom samples were obtained before and at least 3
months after initiation of IFN beta treatment and patients whose serum was
obtained for sILT3 analysis. The individual treatment status with IFN beta in
serum donors is stated in S1 Table. Patients treated with intravenous
glucocorticoids or plasmapheresis during the preceding six weeks were excluded.
In addition age- and sex-matched healthy volunteers were recruited. Control sera
were obtained from patients with malignant melanoma treated at the Ludwig-
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Maximilian University of Munich and the University of Regensburg. Again the
individual treatment status with IFN is indicated in S1 Table.
CSF and paired blood samples were collected from patients that were referred
to the Dept. of Neurology of the University of Erlangen for diagnostic lumbar
puncture. Patients were categorized into two groups: inflammatory neurological
diseases (IND, e.g. viral encephalitis, multiple sclerosis) and non-inflammatory
neurological diseases (NIND, e.g. normal pressure hydrocephalus). None of the
CSF donors were undergoing IFN beta treatment.
Nine MS and three control tissue samples were supplied by the UK Multiple
Sclerosis Tissue Bank (UK Multicentre Research Ethics Committee, MREC/02/2/
39), funded by the Multiple Sclerosis Society of Great Britain and Northern
Ireland (registered charity 207495). Autoptic brain samples were analysed by luxol
fast blue, hematoxylin/eosin staining and CD68 immunohistochemistry as
previously described [31]. Information on the pre-mortem treatment of these
patients with disease modifying drugs was not available.
Isolation and cultivation of peripheral blood mononuclear cells
PBMC were isolated by centrifugation on a Lymphoprep (Fresenius Kabi Norge
AS, Oslo, Norway) density gradient and cultured in RPMI 1640 (Gibco Invitrogen
GmbH, Karlsruhe, Germany) supplemented with 10% of heat inactivated human
AB serum (PAA, Pasching, Austria), glutamine and antibiotics. Cells were grown
at a densitiy of 26106/ml in 12-well plates (Gibco Invitrogen GmbH, Karlsruhe,
Germany) under standard conditions (37uC, 5% CO2). For some experiments
monocytes were purified from PBMC using anti-CD14 microbeads (Miltenyi
Biotech GmbH, Bergisch Gladbach, Germany) and magnetic cell separation
(MACS technology). IFN beta-1a (Rebif, 1000 IE/ml) or 1a,25-Dihydroxyvitamin
D3 (100 nM) were added to the medium as indicated.
Flow cytometry
PBMC were washed twice followed by Fc receptor blocking with human IgG
(Sigma-Aldrich, Munich, Germany). Afterwards cells were incubated for
30 minutes at 4uC with specific monoclonal antibodies: anti-CD14 APC (MOP9,
BD Bioscience, Heidelberg, Germany), anti-CD86 PE (IT2.2, eBioscience,
Frankfurt, Germany), anti-B7-H1 PE (MIH1, eBioscience, Frankfurt, Germany),
anti-B7-H3-PE (RnD Systems), anti-ILT3 PE (ZM4.1, eBioscience, Frankfurt,
Germany), anti-ILT4 PE (42D1, eBioscience, Frankfurt, Germany) and the
respective fluorochrome-conjugated isotypic controls.
For CSF analysis, cells were pelleted by centrifugation and resuspended in
100 ml of 4uC PBS 1% BSA within 30 minutes after the lumbar puncture. CSF and
paired EDTA blood samples were stained with APC conjugated anti-CD14
antibody and PE-conjugated anti-ILT3 antibody or the respective isotype controls
(blood only). Following erythrocyte lysis, cells were analyzed on a FACSCanto II
(BD Biosciences, Heidelberg, Germany). Percentages of positive cells, as well as
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the specific fluorescent indices [geometric mean of the specific antibody
fluorescence divided by the geometric mean of the isotype control antibody
fluorescence] were calculated.
RNA isolation and quantitative PCR
RNA from PBMCs was isolated using the Rneasy Mini Kit (Qiagen, Hilden,
Germany). RNA from frozen tissue sections was purified using RNAzol (Sigma-
Aldrich, Taufkirchen, Germany) according to the manufacturer’s instructions, but
with two subsequent phase separation steps to improve RNA purity. RNA was
transcribed using random hexamers and MuLV reverse transcriptase (Promega,
Mannheim, Germany) or high capacity cDNA Kit (ABI, Darmstadt, Germany).
For expression analysis in PBMCs, PCR and quantification of PCR products was
performed using Ssofast EVA Green Supermix (Biorad Laboratories, Hercules,
CA, USA) on a MyIQ5 Real Time PCR System. The following primers for ILT3
were used during the amplification: forward, 59-CTGCCGAGTCCTCTT-
GTGACC-39; reverse, 59 TGG AGG ACG TTG GAA ATC AGC-39 [12]. Beta-
Actin was used as an endogenous control (forward, 59-AGG ATG CAG AAG GAG
ATC ACT-39, reverse 59-GGG TGT AAC GCA ACT AAG TCA TAG-39).
Quantification of gene expression was performed according to the comparative
cycle threshold method (22DDCT). Samples were normalized to beta-actin and
compared to a reference sample used in all the experiments. Expression of ILT3,
ILT4, B7-H3 and PUM1 in autopsy samples was measured using an Applied
Biosystems 7500 with probes supplied by Applied Biosystems (Taqman Gene
Expression Assays Hs00429000, Hs01629548, Hs00987207, and Hs00206469,
respectively). Relative expression was calculated using PUM1 levels for normal-
isation.
Sandwich ELISA detection of soluble ILT3
Soluble ILT3 ELISA was performed as previously described [12]. In brief,
Maxisorp 96-well plates (Nalge Nunc International) were coated overnight with
1.0 mg/well anti-ILT3 mAb (clone ZL5.7). Free binding sites were blocked with 5%
BSA solution for 1 h at room temperature. After washing with PBS with 0.1%
Tween 20, serum samples were added at a 1:3 and 1:9 dilution and incubated for
1 hour. Detection was performed using 100 ml of biotinylated polyclonal anti-
ILT3 antibody (R&D Systems) at a concentration of 33 ng/ml followed by HRP-
conjugated streptavidin (BD Biosciences). Tetramethylbenzidine was used as a
substrate.
Supporting Information
S1 Fig. Effects of 1a,25 Dihydroxyvitamin D3 in combination with IFN beta on
ILT3 and ILT4 expression in healthy donors. PBMC derived from RRMS
patients were stimulated with 1a,25 Dihydroxyvitamin D3 (100 nM) and/or IFN
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beta (1000IE) over a 48 h period. ILT3 and ILT4 protein expression on CD14+
cells was assessed by flow cytometry. The fold induction is shown (mean + SEM).
A repeated measurement ANOVA and Bonferroni multiple comparison test was
performed to assess statistical significance (* p,0.05; **p,0.005).
doi:10.1371/journal.pone.0115488.s001 (TIF)
S1 Table. Soluble ILT3 in serum samples derived from MS or malignant
melanoma patients. Serum samples were analyzed for soluble ILT3 protein
content by ELISA. From some of the RRMS and melanoma patients, samples
derived from before (untreated) and after initiation of IFN beta or IFN alpha
therapy (IFN therapy) were available. A slash (/) indicates a missing sample, n.d.
(not detectable) indicates that soluble ILT3 serum concentrations were below the
lower level of detection of the assay. Detectable levels of ILT3 were found in 2
patients with RRMS and 2 patients with melanoma. In contrast to the increased
surface ILT3 expression after IFN beta treatment, soluble ILT3 concentrations were
not elevated (at least not above the detection threshold) by IFN beta therapy.
doi:10.1371/journal.pone.0115488.s002 (TIF)
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